Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2017 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for any statement in the transcript that indicates escalation of unit size. The transcript is about RPM International's earnings call. Management discusses various things: Kirker impairment, Flowcrete closure, acquisitions, cost cutting, etc. They talk about acquisitions being small and medium sized product lines. They mention that they have done six acquisitions across six different business units. They say these are "nice fold-in product line acquisitions" and "bread and butter" deals. They don't seem to indicate that the size of deals is escalating. They talk about revenue growth, organic growth, but not about individual deal size increasing. They mention that they are closing underperforming businesses. They talk about capacity constraints at DAP being resolved. They talk about foreign exchange and pension costs. There is no mention of larger orders, contracts, or projects. They talk about infrastructure spending potentially helping, but that's not about escalation of unit size. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size. There is no such description. Management does not say that the average size of new orders has stepped up, or that customers are starting at larger scope, or that follow-on commitments are larger. They talk about acquisitions, but those are not "engagements" in the sense of orders or contracts; they are acquisitions of companies. And they don't say that the acquisitions are getting larger over time. They say they are small and medium sized. Thus, the answer is NO. We need to answer only YES or NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.